An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism
Recruiting
- Conditions
- Venous Thromboembolism
- Registration Number
- NCT06278051
- Lead Sponsor
- Bayer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Inclusion Criteria:At index date, which is the date of first prescription of rivaroxaban<br>or of warfarin during the study period<br><br> - Age less than 18 years<br><br> - Diagnosis of VTE at any point before and including the index date<br><br> - Receiving a prescription/dispensation of rivaroxaban or warfarin<br><br>Exclusion Criteria:<br><br> - none
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of major bleeding in participants treated with rivaroxaban;Clinical characteristics and demographics of participants with pediatric VTE treated with rivaroxaban
- Secondary Outcome Measures
Name Time Method Incidence of major bleeding in participants treated with warfarin;Incidence of bleeding important in pediatrics in participants treated with rivaroxaban and treated with warfarin as reference;Incidence of major bleeding and bleeding important in pediatrics in participants treated with rivaroxaban and in special target patient groups